Meeting
2022 ASCO Annual Meeting
Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).
Authors
Elizabeth Catherine Smyth
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Elizabeth Catherine Smyth , Joseph Chao , Kei Muro , Priscilla Yen , Rolando Eduardo Yanes , Anita Zahlten-Kumeli , Sun Young Rha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT05052801
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4164)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4164
Abstract #
TPS4164
Poster Bd #
147b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).
First Author: Zev A. Wainberg
Poster
2017 ASCO Annual Meeting
Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).
First Author: David E. Gerber
Poster
2023 ASCO Annual Meeting
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.
First Author: Erika P. Hamilton
Poster
2023 ASCO Annual Meeting
Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
First Author: Kohei Shitara